Containing Proteins And Derivatives Patents (Class 424/491)
-
Publication number: 20140099359Abstract: A synthetic platelet includes a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, the peptides including a plurality of von Willebrand factor-binding peptides (VBPs), collagen-binding peptides (CBPs) and an active platelet GPIIb-IIIa-binding peptides (GBPs).Type: ApplicationFiled: April 13, 2012Publication date: April 10, 2014Applicant: Case Western Reserve UniversityInventors: Anirban Sen Gupta, Madhumitha Ravikumar
-
Patent number: 8691261Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.Type: GrantFiled: July 18, 2012Date of Patent: April 8, 2014Assignees: IHI CorporationInventors: Haruki Eguchi, Yoshihiro Ishikawa
-
Publication number: 20140093575Abstract: Systems and methods for coating a particle core with a layer-by-layer film are disclosed.Type: ApplicationFiled: April 23, 2013Publication date: April 3, 2014Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Patent number: 8680032Abstract: The invention relates to microencapsulated colorant granules consisting of a core (A) and a shell (B), whereby the core (A) has a diameter of between 1 and 1000 micrometer and comprises a) a colorant (I), b) microcrystalline cellulose, c) a polyol; and whereby the shell (B) has a thickness of between 1 to 500 micrometer and comprises d) a polymer selected from the group consisting of polycarboxylic acids, vinyl polymers, styrene-(meth)acrylic copolymers, cellulose and cellulose derivatives. The invention further relates to cleansing compositions, such as hand soaps, containing said microencapsulated colorant granules.Type: GrantFiled: July 15, 2010Date of Patent: March 25, 2014Assignee: Clariant Finance (BVI) LimitedInventors: Angela Lachmann, Harald Oswald, Sambit Roy, Sharmad Chandratre
-
Publication number: 20140079787Abstract: The present invention provides methods and compositions for treating hepatocellular carcinoma (HCC) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating HCC comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent, such as an agent that inhibits microtubule disassembly.Type: ApplicationFiled: February 28, 2013Publication date: March 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Winnie YEO, Nathalie WONG
-
Publication number: 20140079788Abstract: The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.Type: ApplicationFiled: March 1, 2013Publication date: March 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Abraxis BioScience, LLC
-
Publication number: 20140072643Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.Type: ApplicationFiled: March 1, 2013Publication date: March 13, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Abraxis BioScience, LLC
-
Publication number: 20140056986Abstract: The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise a taxane and an albumin.Type: ApplicationFiled: March 1, 2013Publication date: February 27, 2014Applicant: Abraxis BioScience, LLCInventor: Abraxis BioScience, LLC
-
Publication number: 20140056815Abstract: Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells.Type: ApplicationFiled: November 1, 2013Publication date: February 27, 2014Inventor: Gholam A. Peyman
-
Publication number: 20140050664Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from soy or lentil plant material or a reactive extract thereof of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. The nanoparticles can be introduced in vivo to conduct enhanced imaging. The nanoparticles can also be introduced in vivo to conduct therapy.Type: ApplicationFiled: October 25, 2013Publication date: February 20, 2014Applicant: The Curators of the University of MissouriInventors: Kattesh V. Katti, Raghuraman Kannan, Kavita K. Katti, Nripen Chanda, Ravi Shukla
-
Publication number: 20140044792Abstract: Methods for producing implantable bone compositions suitable for attaching stem cells thereto, characterized in that bone particles are contacted with an albumin comprising solution. Said bone particles can be mineralized and/or lyophilized bone particles of animal or human origin. Preferably the non-immunogenic albumin comprising solution is lyophilized onto said bone particles. The invention further concerns bone compositions suitable for usin in graft implantation obtainable by said methods.Type: ApplicationFiled: October 7, 2013Publication date: February 13, 2014Applicant: LACERTA TECHNOLOGIES, INC.Inventors: Zsombor Lacza, Miklós Weszl
-
Publication number: 20140044791Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.Type: ApplicationFiled: February 6, 2012Publication date: February 13, 2014Applicant: Case Western Reserve UniversityInventors: James Basilion, Clemens Burda
-
Publication number: 20140044793Abstract: A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 ?m to 20 ?m. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.Type: ApplicationFiled: September 20, 2011Publication date: February 13, 2014Applicant: SPI PHARMA, INC.Inventors: Diane Goll, Cecil W. Propst
-
Publication number: 20140030348Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: March 15, 2013Publication date: January 30, 2014Applicant: NEOS THERAPEUTICS, LPInventors: Mark Tengler, Russell McMahen
-
Publication number: 20140030347Abstract: A composition and a method effective in the production of the composition. The composition is a ready-to-use aqueous suspension in large and small quantities comprising human-fibrinogen-coated human-albumin spheres and the supernatant, said suspension being useful for the treatment of thrombocytopenic patients.Type: ApplicationFiled: July 27, 2012Publication date: January 30, 2014Inventor: Richard C.K. Yen
-
Patent number: 8637440Abstract: A personal cleansing composition includes a surfactant, a thickener, emulsifier and at least one particulate dispersed in the thickener, the at least one particulate being formed of a substantially biodegradable substance. The at least one particulare may include a soy meal based polymer. The soy meal based polymer is both stable and biodegradable. The at least one particulate includes a group of suspended particles added to mechanically scrub the skin of a user or used as a textural ingredient to modify the feel, spreadability or slip of a product. The soy meal based polymer is useful in personal cleansing compositions as an exfoliant, a scrub, a film former or as a filler. The half-life of the composition may be modified as necessary based on the shelf-life of the product.Type: GrantFiled: November 6, 2012Date of Patent: January 28, 2014Inventor: Kim Cervino
-
Publication number: 20140023715Abstract: This disclosure relates to polymer coated particles targeting cancer cells and methods related thereto. In certain embodiments, the disclosure relates to nanoparticles coated with amphiphilic polymers conjugated with molecules useful for targeting tumors, monitoring the location of the nanoparticles administered to a subject by MRI, and viewing the presence of the nanoparticles during optical image-guided surgery.Type: ApplicationFiled: March 30, 2012Publication date: January 23, 2014Applicant: EMORY UNIVERSITYInventors: Lily Yang, Gee Young Lee, Malgorzata Lipowaska, Hui Mao
-
Patent number: 8632803Abstract: A pharmaceutical composition containing a therapeutic protein which is particularly amenable to oral administration by providing stability in the gastrointestinal tract. Insoluble fibrils or aggregates of the therapeutic protein in the pharmaceutical composition are encapsulated in a lipidated glycosaminoglycan particle, coated with a multi-layer of lipids and lipid-glycosaminoglycan conjugates, or present as unencapsulated and uncoated insoluble fibrils or aggregates.Type: GrantFiled: February 18, 2009Date of Patent: January 21, 2014Assignee: Ramot At Tel-Aviv University Ltd.Inventors: Yaron Dekel, Rimona Margalit
-
Publication number: 20140017323Abstract: The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”).Type: ApplicationFiled: March 1, 2013Publication date: January 16, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Abraxis BioScience, LLC
-
Publication number: 20140017324Abstract: An L-menthol-containing multiparticulate formulation includes a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. The enteric coated cores are effective to release at least about 35% of the L-menthol within about two hours, and at least about 80% of the L-menthol within about eight hours after being placed in an environment having a pH of 5 to 8. The L-menthol multiparticulate formulation can be used to treat gastrointestinal disorders.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Applicant: ZX PHARMA, LLCInventors: SYED SHAH, FRED HASSAN, DANIEL HASSAN, SARAH HASSAN
-
Patent number: 8628851Abstract: The invention provides a method for encapsulating a liquid, which method comprises the steps of providing a suspension of droplets of the liquid to be encapsulated; stabilizing the suspension of droplets with a surfactant; adding a layered inorganic material to the stabilized suspension; and subjecting the suspension to a treatment which establishes that a shell of a hybrid material is formed around the droplets, which hybrid material comprises at least part of the inorganic material and at least part of the surfactant. The invention further provides encapsulated liquid droplets obtainable by said method.Type: GrantFiled: March 6, 2006Date of Patent: January 14, 2014Assignee: Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek TNOInventors: Sabine Fischer, Hartmut Rudolf Fischer, Jacobus Eversdijk, Renz Jeroen Van Ee
-
Publication number: 20140010885Abstract: A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.Type: ApplicationFiled: January 18, 2012Publication date: January 9, 2014Inventors: Miguel de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
-
Publication number: 20140010886Abstract: The disclosure relates to uses of saccharide binding moieties, e.g., lectins for targeting cells, typically cancer stem cells. In certain embodiments, the disclosure relates to conjugates comprising: a) a saccharide binding moiety; b) a polymer; and c) a therapeutic agent; wherein the saccharide binding protein is covalently attached to the polymer.Type: ApplicationFiled: April 4, 2012Publication date: January 9, 2014Applicants: GEORGIA TECH RESEARCH CORPORATION, EMORY UNIVERSITYInventors: David Scott Wilson, Rodney J. Nash, Prasanthi Chappa, Constantinos G. Hadjipanayis
-
Patent number: 8617610Abstract: Disclosed are compositions including powdered green tea extract and a powdered preparation comprising polyunsaturated fatty acids. Also disclosed are methods of preparing the compositions and using the compositions in food products, as well as food products containing or that are prepared from the compositions.Type: GrantFiled: May 21, 2012Date of Patent: December 31, 2013Assignee: DSM Nutritional Products AGInventors: Amber Lynn Gareau, Sharon Ann Spurvey Pittman, Lariza Beristain Taboada
-
Publication number: 20130336891Abstract: Formulation of acoustically activatable particles having low vaporization energy and methods for using same are disclosed. According to one aspect, a method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, performing one of: causing the first substance to condense to a liquid phase, and extruding or emulsifying the first substance into or in the presence of a second substance to create a droplet or emulsion in which the first substance is encapsulated by the second substance; or extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion.Type: ApplicationFiled: October 11, 2011Publication date: December 19, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Paul A. Dayton, Paul S. Sheeran, Terry O. Matsunaga, Mark A. Borden
-
Patent number: 8609126Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.Type: GrantFiled: May 25, 2012Date of Patent: December 17, 2013Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Eugene Michal, Shubhayu Basu, Hai-Chien Kuo
-
Publication number: 20130330402Abstract: This invention describes a method whereby autoimmune antinuclear antibodies are used as a targeting agent to deliver drug nanoparticles or drug liposomes to the tumor or disease site. The antinuclear antibodies have the propensity to localize in areas of tissue necrosis where dead cells have released their nuclear material into the extracellular environment. Many tumors have areas of necrosis that can be targeted using antinuclear antibody coated drug nanoparticles or liposomes. Similarly, many infectious diseases have areas of necrosis and can also be targeted using antinuclear antibody coated drug nanoparticles or liposomes. Similarly, many immune disorders such as rheumatoid arthritis and osteoarthritis have areas of inflammation where there is cell death, and these inflammatory sites can also be targeted using antinuclear antibody coated drug nanoparticles or liposomes.Type: ApplicationFiled: August 19, 2013Publication date: December 12, 2013Inventors: HENRY J. SMITH, JAMES R. SMITH
-
Publication number: 20130323311Abstract: This invention relates to compositions comprising collagen binding peptides coupled to nanoparticles. The invention also relates to a method of imaging a collagenous matrix using a composition comprising collagen binding peptides coupled to nanoparticles.Type: ApplicationFiled: February 16, 2012Publication date: December 5, 2013Applicant: PURDUE RESEARCH FOUNDATIONInventors: John E. Paderi, Alyssa Panitch
-
Publication number: 20130323310Abstract: Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 ?m, the particles being swellable by hydration to a size that is greater than 6 ?m volume mean diameter, and a working agent entrapped in the polymer network of each of the plurality of biodegradable particles.Type: ApplicationFiled: April 19, 2013Publication date: December 5, 2013Applicant: STC.UNMInventors: Hugh D. Smyth, Martin J. Donovan
-
Publication number: 20130316006Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: ApplicationFiled: May 3, 2013Publication date: November 28, 2013Applicant: Kala Pharmaceuticals, Inc.Inventor: Kala Pharmaceuticals, Inc.
-
Patent number: 8591928Abstract: A pesticide granule is provided that includes a base carrier particle. A liquid pesticide coating is applied to the particle surface. The coating may contain adjuvants. The coating has sufficient tack to adhere a second powdered pesticide to the carrier particle. The usage of tackifying agents to render the particle surface tacky enough to adhere powdered pesticide is reduced or eliminated. The powdered pesticide is sized to a mean diameter of less than 10% of the carrier diameter to promote adhesion. The synergistic rapid acting pesticide delivery associated with the granule results in the usage of less pesticide to control a given pest with reduced environmental impact. Bifenthrin is a representative of the liquid pesticide.Type: GrantFiled: January 3, 2011Date of Patent: November 26, 2013Assignee: The Andersons, Inc.Inventors: Timothy D. Birthisel, James R. Lynch, Matthew G. Johnston
-
Publication number: 20130309313Abstract: Disclosed are compositions including powdered green tea extract and a powdered preparation comprising polyunsaturated fatty acids. Also disclosed are methods of preparing the compositions and using the compositions in food products, as well as food products containing or that are prepared from the compositions.Type: ApplicationFiled: May 21, 2012Publication date: November 21, 2013Applicant: OCEAN NUTRITION CANADA LIMITEDInventors: Amber Lynn Gareau, Sharon Ann Spurvey Pittman, Lariza Beristain Taboada
-
Patent number: 8568784Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.Type: GrantFiled: November 10, 2010Date of Patent: October 29, 2013Assignee: Morehouse School of MedicineInventors: James W. Lillard, Rajesh Singh, Shailesh Singh
-
Publication number: 20130273169Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
-
Publication number: 20130266659Abstract: The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise a taxane and an albumin.Type: ApplicationFiled: May 20, 2011Publication date: October 10, 2013Inventors: Neil P. Desai, Patrick Soon-Shiong
-
Patent number: 8551525Abstract: Compositions, materials, methods and kits for bone grafting are described. In some embodiments, a bone graft composition includes about 15% to about 20% by weight collagen, about 55% to about 70% by weight bioactive glass, and about 15% to about 30% by weight a calcium phosphate. The bioactive glass and the calcium phosphate together are about 80% to about 85% by weight of the bone graft composition. In some embodiments, a bone graft composition includes a collagen matrix and a plurality of bioactive glass particulates dispersed throughout the collagen matrix. The collagen matrix is about 20% to about 60% by weight of the bone graft composition, and the bioactive glass is about 40% to about 80% of the bone graft composition. In some embodiments, a majority of the bioactive glass particulates are about 53 ?m to about 425 ?m in size.Type: GrantFiled: December 23, 2010Date of Patent: October 8, 2013Assignee: Biostructures, LLCInventors: Russell L. Cook, Duraid S. Antone
-
Publication number: 20130259944Abstract: This disclosure relates to methods and compositions for treating cancer with platinum particles. In certain embodiments, the disclosure relates to platinum particle coated with a polysaccharide, such as a heparin or modified heparin, conjugated to a polypeptide that has affinity for a cell surface cancer marker and uses related thereto.Type: ApplicationFiled: March 8, 2013Publication date: October 3, 2013Applicant: EMORY UNIVERSITYInventors: Dong M. Shin, Shuming Nie, XiangHong Peng, Yiqing Wang
-
Publication number: 20130259946Abstract: Multilayer films comprised of polypeptide epitopes and a toll-like receptor ligand. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a virus, bacteria, fungus or parasite.Type: ApplicationFiled: March 14, 2013Publication date: October 3, 2013Applicant: ARTIFICIAL CELL TECHNOLOGIES, INC.Inventors: Thomas J. Powell, James Gorham Boyd
-
Publication number: 20130259945Abstract: Multilayer films comprise polypeptide epitopes from Plasmodium falciparum, specifically a circumsporozoite T1, B or T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a Plasmodium protozoan.Type: ApplicationFiled: March 14, 2013Publication date: October 3, 2013Applicant: ARTIFICIAL CELL TECHNOLOGIES, INC.Inventor: Thomas J. Powell
-
Publication number: 20130243866Abstract: A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in ?-sheet structure dominant silk microsphere structures having about 2 ?m in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.Type: ApplicationFiled: May 7, 2013Publication date: September 19, 2013Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. KAPLAN, Xiaoqin WANG
-
Patent number: 8535923Abstract: Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin.Type: GrantFiled: April 27, 2010Date of Patent: September 17, 2013Assignee: Cytonet GmbH & Co. KGInventors: Krasimira Aleksandrova, Peter Pediaditakis, Jo Salisbury, Wolfgang Rüdinger
-
Publication number: 20130230580Abstract: Provided are therapeutics, uses and methods in which neuro-regenerative therapy using neuroprotective agents, or anti-neuropathic agents, to prevent loss or restore hematopoietic capacity and progenitor mobilization.Type: ApplicationFiled: September 14, 2011Publication date: September 5, 2013Inventors: Paul S. Frenette, Daniel Lucas-Alcaraz
-
Patent number: 8524195Abstract: Iron oxide nano contrast agents for Magnetic Resonance Imaging which have superior T2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic FeO nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic FeO nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic FeO nanoparticles in water to oxidize FeO; and exposing the oxidized hydrophilic FeO nanoparticles to an acidic buffer to dissolve and remove interior unoxidized FeO portions, and thereby to form Fe3O4 nanoparticles having an interior space.Type: GrantFiled: December 29, 2010Date of Patent: September 3, 2013Assignee: Korea Basic Science InstituteInventors: Chulhyun Lee, Sung Lan Jeon, Min Kyung Chae, Jee-Hyun Cho, Eun Ju Jang
-
Publication number: 20130224123Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: December 4, 2012Publication date: August 29, 2013Applicant: Alkermes Pharma Ireland LimitedInventor: Alkermes Pharma Ireland Limited
-
Patent number: 8512754Abstract: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.Type: GrantFiled: September 2, 2011Date of Patent: August 20, 2013Inventor: David Needham
-
Patent number: 8512756Abstract: Collagen compositions, methods for preparing those collagen compositions, and graft compositions formed from those collagen compositions are provided. In particular, methods of isolating collagen that exhibits an enhanced rate of polymerization and enhanced microstructural and mechanical properties upon polymerization, such collagen compositions, and graft compositions formed from such collagen compositions are provided.Type: GrantFiled: December 20, 2011Date of Patent: August 20, 2013Assignee: Purdue Research FoundationInventors: Sherry L. Voytik-Harbin, Seth Kreger, Brett Bell, Jennifer Bailey
-
Publication number: 20130209542Abstract: A pharmaceutical carrier and a pharmaceutical composition for inhibiting angiogenesis are disclosed. The pharmaceutical carrier of the present invention comprises: a drug carrier; and a polypeptide linked to a surface of the drug carrier, wherein the polypeptide comprises a receptor binding domain of vascular endothelial growth factor.Type: ApplicationFiled: November 19, 2012Publication date: August 15, 2013Applicant: NATIONAL CHIAO TUNG UNIVERSITYInventor: National Chiao Tung University
-
Publication number: 20130209566Abstract: The present invention provides a novel nanoparticle drug delivery system generated from poly(ortho ester) polymers with sustained drug release capability and can be functionalized to allow for systemic delivery to various organ systems throughout the body. One important aspect of this invention is that the nanoparticle drug delivery system generated from poly(ortho ester) polymers encapsulate several types of drugs in poly(ortho ester) nanoparticles, including but not limited to lipophilic, hydrophilic small and large molecules and also hydrophilic and lipophilic dyes by adopting appropriate emulsion techniques. These poly(ortho ester) nanoparticles are biodegradable, biocompatible and controlled release drug delivery system with zero order kinetics, which can be used in various biomedical applications such as eye-related diseases, cancer, arthritis, etc.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Inventors: MONICA JABLONSKI, MALLIKA PALAMOOR
-
Publication number: 20130202709Abstract: The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.Type: ApplicationFiled: May 20, 2011Publication date: August 8, 2013Inventors: Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20130202708Abstract: The present invention is related to a viral particle released after infection of mammalian cells by human cytomegalovirus (HCMV), wherein a) the particle is surrounded by a lipid membrane in which viral glycoproteins are embedded, b) the particle contains neither viral DNA nor capsids; and c) the particle contains a fusion protein comprising one or more parts of the T-cell antigen pp65 and at least one heterologous peptide, and wherein the at least one heterologous peptide is inserted at amino acid position W175 or A534 of the amino acid sequence of the T-cell antigen pp65.Type: ApplicationFiled: April 6, 2011Publication date: August 8, 2013Applicant: Valzine Projekt Management GmbHInventors: Sabine Becke, Sabine Reyda, Bodo Plachter